RZLT Rezolute, Inc. Insider Trading

CFO Evans Daron bought 10,000 shares at $2.85 on 2026-03-30; prior same-ticker buys 80% well-timed at 90d, current price -72.1% from 52-week high.

CFO Evans Daron purchased 10,000 shares at $2.85, bringing holdings to 414,462 shares—a 2.5% increase. His track record at RZLT demonstrates strong timing discipline: 4 of 5 prior trades were well-timed on the 90-day basis, with three consecutive December purchases returning 52.0% to 54.0% in 30 days and 45.0% to 46.9% in 90 days. However, the company remains unprofitable with full-year net income of -$22,774,000.00, and the stock is currently -72.1% from its 52-week high of $10.94. The insider's cross-ticker buy history shows an 83.33% 90-day win rate with +59.6% average 90-day return, suggesting execution capability that has translated to RZLT specifically in recent months. The timing of this purchase—after a -5.0% 30-day decline—occurs in context of structural unprofitability and deep valuation drawdown from peak.

Director Hogenhuis buys 5,650 shares of RZLT at $1.69; stock -81.6% from 52-week high amid cluster buy pattern

Hogenhuis Wladimir (Director) purchased 5,650 shares at $1.69 on 2025-12-16, increasing holdings to 119,675 shares (a +5.0% increase). The purchase occurs amid severe price deterioration: RZLT is -81.6% from its 52-week high of $10.94 and -80.3% over the past 30 days. The company is unprofitable with net income of $-18,150,000.00 against a market cap of $186,382,339.32. At the same-ticker level, Hogenhuis's prior four RZLT purchases showed mixed 90-day outcomes (2 profitable, 2 unprofitable), with timing success in only 50% of instances. The transaction occurs within a cluster of 4 other insider buys in the past 14 days, indicating coordinated director-level activity during a period of sharp stock decline. The combination of deep price weakness, unprofitability, and group buying activity warrants investor review of whether insiders view current valuations as compelling or whether broader strategic factors are driving synchronized purchases.

CMO Brian Roberts bought 28,000 RZLT shares at $1.70 on 2025-12-16 (+10.0% of holdings); stock down 81.6% from 52-week high amid cluster buy

Chief Medical Officer Brian Roberts purchased 28,000 shares at $1.70, raising his holdings to 308,352 shares post-transaction. His prior 5 buys at RZLT exhibited a 100% win rate at the 90-day mark, with returns of +44.0%, +33.5%, +31.5%, +33.6%, and +31.8%, suggesting consistent timing accuracy in this stock. However, the current price of $2.01 reflects severe compression—down 81.6% from the 52-week high of $10.94 and down 80.3% over the past 30 days—amid fundamentals showing $-18.2M net income. The timing of this buy alongside 4 other insiders' purchases within 14 days creates a cluster pattern that may indicate management's view of valuation at depressed levels, though the company remains unprofitable.

CFO Evans Daron bought 45,000 shares at $1.77 avg; stock down 85.1% from 52-week high, held post-transaction shows net short position now closed

Evans Daron, CFO of Rezolute, executed 3 separate purchases totaling 45,000 shares for $79,577.50 at an average price of $1.77 on 2025-12-15, converting a pre-transaction short position of -38,000 shares into a long position of 7,000 shares. The timing occurs at a significant trough: the stock trades 85.1% below its 52-week high of $10.94, having declined 83.5% over the past 30 days. His prior trades at Rezolute show a 3-of-4 pattern of well-timed entry points at the 90-day mark, with two prior buys returning +44.9% and +101.0% respectively; however, fundamentals remain pressured with the company reporting $-18,150,000.00 net income over its most recent full fiscal year. A cluster of buy activity has emerged, with 2 other insiders also purchasing within the past 14 days, suggesting coordinated conviction or pre-planned acquisition activity. The extreme price decline and insider accumulation at these depressed levels warrants scrutiny of whether this represents informed repositioning or response to undisclosed material developments.

CCO Karnawat buys 12,100 shares at blended $1.62 while stock down 85.1% from 52-week high; cluster buy pattern detected

Karnawat Sunil Ratilal, Chief Commercial Officer, executed 2 separate purchases totaling 12,100 shares for $19,598.80 on 2025-12-15, increasing his holdings by 20.4% from 59,442 to 71,542 shares. The transactions occurred at prices of $1.62 and $1.60 per share, against a current market price of $1.63 and a 52-week high of $10.94—placing the stock at -85.1% from its peak and down 83.5% over the past 30 days. The company is operating at a loss with net income of $-18,150,000.00. Notably, 2 other insiders also purchased shares within the past 14 days, forming a cluster buy pattern, which may indicate a coordinated assessment of value at depressed levels, though such patterns can also simply reflect reactive behavior to price weakness rather than forward-looking conviction about business recovery.

CEO Elam Nevan C bought 32,000 shares at $1.59; stock down 85.1% from 52-week high amid cluster buy by 2 other insiders in past 14 days.

CEO Elam Nevan C purchased 32,000 shares at $1.59, expanding holdings by 5.3%, during a period when Rezolute is trading down 85.1% from its 52-week high of $10.94. The company reported a net loss of $18,150,000.00 over its most recent full fiscal year, placing it in a financially stressed position. Notably, 2 other insiders also bought within the past 14 days, forming a cluster buy pattern. Historically, Elam's prior two buys at Rezolute (on 2025-03-27 and 2024-02-26) both posted positive 90-day returns of 35.3% and 52.2%, respectively, suggesting prior purchases at this ticker were followed by price recovery. The current purchase occurs as the stock trades at a severe discount to recent highs, creating a critical data point for assessing insider confidence amid losses and deteriorating valuations.

CMO Roberts buys 2,500 RZLT shares at $4.38; 5th buy in 12 months, all well-timed at 90d mark; cluster of 4 insiders buying within 14 days

Roberts purchased 2,500 shares at $4.38, expanding his holdings by 19.2% from 13,000 to 15,500 shares. This is his fifth open-market purchase of RZLT in the past year, and each prior buy at this ticker generated positive 90-day returns (ranging 31.5% to 59.9%), establishing a pattern of well-timed entry points. The broader context shows three additional insiders acquiring shares within the past 14 days, indicating coordinated insider confidence. However, Rezolute remains unprofitable with a net loss of $18,914,000 for the most recent full fiscal year, so the fundamental backdrop remains challenged; the cluster-buy signal must be weighed against ongoing operational losses and a stock trading 27.7% below its 52-week high despite recent momentum (30-day gain of 12.5%).

CFO Evans Daron bought 5,000 shares of RZLT at $4.05; cluster pattern with 2 other insiders buying within 14 days amid 90-day +55.3% recovery.

Evans Daron purchased 5,000 shares at $4.05, bringing his total holding to 268.9K shares. This purchase occurs within a cluster of 3 insider buys across a 14-day window, a notable signal of coordinated confidence from the executive team. The timing context is significant: the stock has recovered +55.3% over 90 days and is currently +9.0% over 30 days, yet remains -28.9% from its 52-week high of $5.96. Daron's prior trades at RZLT show a 60% win rate at the 90-day mark (3 of 5 prior buys yielded positive 90d returns), though the company remains unprofitable with net income of $-18.9M against a market cap of $362.6M. The convergence of cluster buying activity, recovery momentum, and a CFO's willingness to add shares despite ongoing losses warrants tracking for whether this reflects insider assessment of near-term operational improvement or structural valuation opportunity.

Director Kim Young-Jin bought 1,230,769 shares of RZLT at $3.25 for $3,999,999.25 on 2025-06-13; holdings now 8,423,386 shares (+17.1%)

Kim Young-Jin's $4.0M discretionary purchase of 1,230,769 shares at $3.25 represents a substantial 17.1% increase to his stake in Rezolute, demonstrating material capital commitment despite the company's $-18,914,000 net loss in its most recent fiscal year. His prior two buys at this ticker showed strong 90-day returns (17.0% and 202.5%), suggesting pattern recognition of value entry points, though his 90-day track record across all tickers averages 59.4% returns—establishing a baseline for evaluating whether this trade meets his historical risk/reward profile. The current price of $4.03 places this transaction 24% below the 52-week high of $5.96, offering context on the entry timing relative to recent volatility. Directors' accumulations of this magnitude in unprofitable companies merit attention as signals of conviction or potential strategic visibility into near-term catalysts.

Director Nerissa Kreher buys 3,076 shares of RZLT at $3.25; holdings rise 8.9% amid -32.4% drawdown from 52-week high.

Kreher, a Director, purchased 3,076 shares at $3.25 on 2025-06-13, increasing her stake by 8.9% to 37,576 shares. The transaction occurred with the stock trading 32.4% below its 52-week high of $5.96 and 24.1% above its 52-week low of $2.47. Rezolute is operating unprofitably with net income of $-18.9M in its most recent fiscal year, which is material context for insider accumulation. The 90-day price momentum of +39.4% suggests recent recovery following the broader decline, placing this purchase in a period of improving sentiment after significant weakness.